Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study. - van der Wel JWT; Ernst SM; Jebbink M; van den Broek D; Badrising SK; Steinbusch LC; Ruiter G; Theelen WSME; van Veggel BAMH; Smit J; Dingemans AM; Paats MS; et al. (Lung cancer (Amsterdam, Netherlands), 2025)